Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 3/20 | 0.77 |
| ▸ | TK2 | O00142 | 2/20 | 0.55 |
| ▸ | CDA | P32320 | 1/20 | 0.47 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.47 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.47 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.47 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.47 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.46 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.46 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL368853 | 1.00 | PYGM (0.77) | PYGMTK2CDASLC28A1SLC28A2 | |
| SCHEMBL12642313 | 1.00 | PYGM (0.77) | PYGMTK2CDASLC28A1SLC28A2 | |
| SCHEMBL720545 | 1.00 | PYGM (0.77) | PYGMTK2CDASLC28A1SLC28A2 | |
| SCHEMBL6820491 | 0.90 | PYGM (0.77) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL6820494 | 0.90 | PYGM (0.77) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL6820485 | 0.90 | PYGM (0.77) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL158910 | 0.88 | PYGM (0.97) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL6758925 | 0.88 | PYGM (0.97) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL12143148 | 0.88 | PYGM (0.97) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL2579064 | 0.88 | PYGM (0.97) | PYGMTK2SLC28A1SLC28A2SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080170993-A1 | THYMIDINE ANALOGS FOR IMAGING | BAYER SCHERING PHARMA AG (DE) | 2008-07-17 | — | — | US | disclosed |
| WO-2008049644-A1 | THYMIDINE ANALOGS FOR IMAGING | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-05-02 | — | — | WO | disclosed |
| EP-1916003-A1 | Thymidine analogs for imaging | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-04-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080170993-A1 | THYMIDINE ANALOGS FOR IMAGING | TK1, TYMP, TK2 | PYGM 767/4885TK2 3/4885CDA 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.